AU784322B2 - A process for isolation of osteopontin from milk - Google Patents

A process for isolation of osteopontin from milk Download PDF

Info

Publication number
AU784322B2
AU784322B2 AU23528/01A AU2352801A AU784322B2 AU 784322 B2 AU784322 B2 AU 784322B2 AU 23528/01 A AU23528/01 A AU 23528/01A AU 2352801 A AU2352801 A AU 2352801A AU 784322 B2 AU784322 B2 AU 784322B2
Authority
AU
Australia
Prior art keywords
osteopontin
milk
process according
adjusted
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU23528/01A
Other versions
AU2352801A (en
Inventor
Kristian Albertsen
Dereck Chatterton
Hans Henrik Holst
Steen Ostersen
Esben Skipper Sorensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA filed Critical Arla Foods AMBA
Publication of AU2352801A publication Critical patent/AU2352801A/en
Application granted granted Critical
Publication of AU784322B2 publication Critical patent/AU784322B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Dairy Products (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Description

WO 01/49741 PCT/DK01/00005 A process for isolation of osteopontin from milk The present invention relates to a new process for isolation of osteopontin from milk.
Osteopontin (OPN) is a secreted adhesive glycophosphoprotein originally isolated from the collagenous extra cellular matrix of mineralized bone (Franzen A, Heinegard, D. 1985. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 232:715-724.). In the recent years, osteopontin has been found to be expressed by a number of different cell types including osteoblasts, arterial smooth muscle cells, leukocytes, several types of epithelial cells and transformed cells of different lineages (Denhardt DT, Butler WT. Chambers AF, Senger DR. 1995.
Osteopontin: role in cell signalling and adhesion. Ann. N.Y. Acad. Sci., 760).
Accordingly, OPN has been detected in many tissues including kidney, placenta, secretory epithelia and ganglia of the inner ear, and smooth muscle of the vascular system (Butler WT, Ridall AL, McKee MD.1996.Osteopontin. In Bilezekian JP, Rai LG, Rodan GA (eds.) Principles of bone biology. Academic Press, San Diego, CA, pp. 167-181. Furthermore OPN is also present in many body fluids, notably plasma, urine, bile and milk, and it displays elevated expression in many transformed cells (Senger DR, Peruzzi CA, Gracey CF, Papadopoulos A, Tenen DG. 1988. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 48: 5770-5774).
Osteopontin is highly acidic with approximately 25% of the amino acid being aspartate/aspartic acid and glutamate/glutamic acid as well as a significant number of phosphorylated amino acids (Serensen ES, Petersen TE. 1994 Identification of two phosphorylation motifs in bovine osteopontin. Biochem.
Biophys. Res. Commun. 198:200-205; Sorensen, ES, Hejrup, P, Petersen, TE. 1995. Posttranslational modifications of bovine osteopontin: Identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci.
4:2040-2049).
Osteopontin contains an RGD (arginine, glycine, aspartate) integrin-binding sequence, and it can promote attachment of cells to various surfaces, for example the attachment of osteoblasts to bone during bone remodelling. In WO 01/49741 CT/DK01/00005 WO 01/49741 addition to cell attachment capability, osteopontin can act as a cytokine.
Other proposed uses or roles for osteopontin include chemotaxis and inhibition of nitric oxide synthase expression.
Thus, osteopontin has been proposed for use as a pharmaceutical agent. EP 705842 proposes the use of osteopontin in diagnosis, prophylaxis and therapy of osteoarthritis and rheumatiod arthritis. Osteopontin is also believed to play a role in enhancing bone growth and wound healing in mammals, cf. for example EP 942452 and WO 9933415. Further, osteopontin has been proposed for inhibition of nitric oxide, cf. US 5695761. Osteopontin has also been proposed for solubilization of divalent metal ions for addition to foods, cf. abstract of JP 9173018.
Osteopontin has been isolated in research scale amounts (micrograms to low milligram's scale) from a number of tissues and fluids, including mineralized bone. However, there is a huge demand for osteopontin for experimental as well as for industrial use. All known processes for isolating osteopontin are at experimental scale giving too small amounts for industrial use.
Serensen, ES, Petersen T.1993. Journal of Dairy Research 60, 189-197, Purification and characterization of three proteins isolated from the proteose peptone fraction of bovine milk describes a method involving TCA, trichloro acetic acid, precipitation of proteins. This method is not compatible with production of food ingredients, because TCA is not allowed in food products.
Furthermore, the method includes gel filtration, which is not suitable for largescale production.
Bayless KJ, Davis GE, Meininger GA. 1997. Protein Expression and Purification 9, 309-314, Isolation and biological properties of osteopontin from bovine milk describes a method including ion-exchange and two steps of hydrophobic chromatography on phenyl-separose columns. The complexity of the process, and especially the hydrophobic chromatography makes the method inapplicable for large-scale purification of osteopontin.
Senger DR, Peruzzi CA, Papadopoulos A, Tenen DG. 1989. Biochimica et Biophysica Acta 996, 43-48. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin proposes a purifi- P OPER\Ma20(5\254 1710 076 do- I -3cation method. The purification method described for human milk involves barium citrate affinity as well as reverse phase HPLC chromatography, which makes it inapplicable for large-scale purification.
The present invention is directed to solving or improving upon one or more of the above problems. The invention discloses a process for large-scale purification or isolation of osteopontin from bovine milk (and milk from other domesticated milk producing mammals e.g. goat, sheep, buffalo, lama, camel, etc.). Milk osteopontin is highly preferred because it occurs naturally in milk from domestic animals. According to the invention osteopontin is isolated by techniques approved for dairy foods production. This food-grade osteopontin can therefore be used as an ingredient in food products for human consumption without any risks.
The present invention relates to a process for isolation of osteopontin from milk by pH adjustment, wherein a milk material containing osteopontin and a material containing calcium are mixed to obtain a calcium concentration of 0.05-0.2% and is pH adjusted to 3.5 to 5.0 to keep osteopontin in solution while precipitating other milk constituents of to 6.0 to 8.5 to aggregate or bind osteopontin while removing other milk constituents in S. solution.
The process can be performed in one or more steps. It is also possible to combine the steps of keeping osteopontin in solution and binding or aggregating it.
In the process of the invention the raw material is preferably based on milk containing 25 osteopontin. Whey is a good raw material, since the casein proteins contained therein have been removed. Especially whey originating from chemical acidifying of milk is suitable, because its osteopontin is intact. On the other hand, the osteopontin contained S. in cheese whey can be partially hydrolysed. However, it is not yet known whether this •reduces or completely destroys the properties of osteopontin.
Separation of osteopontin from denatured and precipitated protein can be performed by microfiltration or centrifugation as normally performed in the dairy industry.
The pore size can be from 0.1 to 1.4 tm. Ceramic filters are especially well suited owing to mechanical stability and long life. The separation can take PCT/DKOI/O0005 nra 1 nA~ AI WJ U110Y IV 4 place at temperatures f-om 10 to 80 50 55 OC are especially well suited owing to great capacity and stable bacteriological conditions.
All types of anion exchangers can be used. Here a DEAE Sepharose fast flow exchanger is used. During the ion exchange pH can vary from approx. 3 to approx. 6.
The steps involving solution or solubilization of osteopontin or aggregation or binding of osteopontin can be combined in one process. The product streams can be treated in different ways before and/or after these steps to concentrate, separate, dry or perform other processes commonly used in the diary industry. Thus e.g. microfiltration can be used. The person skilled in the diary art will easily determine a proper filter, cf. e.g. Tetra Paks "Dairy processing Handbook" (1995), pp 123 132.
Normally it is preferred to concentrate whey before starting the process of the invention to reduce the amount of water to treat. For preconcentration of whey any conventional ultrafiltration system can be used: plate and frame; hollow fibre, tubular, ceramic and spiral, etc. Spiral systems are especially well suited from an economic point of view for the time being. Any membrane which does not allow osteopontin to pass through the membrane is suitable.
The pore size of such membranes is 20,000 D or less. Suitable membranes are e.g. Koch HFK131, Desal PW or similar membranes.
The soluble Ca source can be any soluble calcium compound, such as calcium hydroxide, calcium chloride or calcium acetate. Calcium nitrite and calcium nitrate is also useable, but will normally not be recommended, if osteopontin is to be used in the food industry.
To aggregate or bind osteopontin to an insoluble Ca source use can be made of Ca 3
PO
4 or other insoluble Ca source. pH adjustment to precipitate calcium phosphate or another insoluble salt with osteopontin can be within the range 8.5. The pH range 6.5 8.0 is particularly well suited. Especially, pH about 7.0 is suitable. Any base can be used: organic as well as inorganic, as pH adjustment agent in this process. Especially the bases NaOH, KOH, Ca(OH) 2 are suitable. Especially NaOH is suitable.
WO 01/49741 PCTIDK01/00005 pH adjustment to keep osteopontin in solution is 3.5 to 5.0, preferably 4.0 4.6. pH 4.2 is most preferred. For the pH adjustment any organic or inorganic acid can be used. Hydrochloric acid is especially suitable owing to strength and price. If the milk starting material containing osteopontin also contains natural calcium from the milk less calcium is to be added or no calcium at all.
Also, use of Ca(OH) 2 for pH adjustment can minimise the amount of other Ca source. Normally a suitable amount will be one where the concentration of calcium in the solution is There is no lower limit, but less than about 0.05% per protein% will give a reduced yield of osteopontin. 0.1% of calcium will be effective, but the yield of osteopontin is reduced compared to using 0.2% of calcium. Concentrations of calcium up to 0.4% have been tried.
However, only little increase is obtained by concentrations above 0.2%.
Therefore, 0.2% is preferred, but also 0.3% could be used.
Separation of precipitated calcium phosphate or another solid Ca source containing osteopontin can be separated from the rest by any usual method, such as microfiltration or centrifugation. The pore size can be from 0.1 to 1.4 ltm. Ceramic filters are especially well suited owing to mechanical stability and long life. The separation can take place at temperatures from 10 to SC. 50 55 0 C are especially well suited owing to great capacity and stable bacteriological conditions.
For the separation of osteopontin from dissolved calcium salt any ultrafiltration system can be used: plate and frame; hollow fibre, tubular, ceramic and spiral, etc. Spiral systems are especially well suited from an economic point of view. Any membrane which does not allow osteopontin to pass through the membrane can be used. The nominal pore size of such membranes is typically 20,000 D or less. Suitable membranes are e.g. Koch HFK328, Desal PV or similar membranes. All types of anion exchangers can be used. Here DEAE Sepharose fast flow exchanger is used.
During the ion exchange pH can vary from approx. 3 to approx. 6.
Germ filtration of whey protein concentrate, WPC, retentate before the pH adjustment to 7.0 in order to precipitate Ca 3 (PO4) 2 or another solid with osteopontin produces a purer aggregate, which will also give a purer product for PCT/DK01/00005 WOi nII017I further processing in the processes and thus also a little purer osteopontin products.
The following examples are intended to illustrate but not limit the present invention.
Example 1 1000 kg of casein whey with pH 4.55, 0.53% protein, approximately 20 ppm osteopontin and 4.50% dry matter are concentrated in a spiral ultrafiltration plant with membranes having a nominal pore size so that the proteins do not pass through the membrane. Typical nominal pore size is 10,000 D. The temperature during the filtration is 50 OC and the mean pressure is 3.5 bars. Concentration is carried on until 900 kg of permeate, which do not contain osteopontin, are removed. During the concentration mean flux is 45.6 litres/m 2 100 kg of retentate with pH 4.55, 3.86% protein, approx.
200 ppm osteopontin and 10.3% dry matter are left.
The 100 kg of retentate are pasteurized at 68 C for 15 sec and cooled to oC. Hereafter pH is adjusted to 7.0 with 6% NaOH.
After being allowed to stand for 2 hours, microfiltration is performed on 0.1.4 ipm ceramic membranes at 500C with a mean pressure of 4.0 bars. Diafiltration is carried out with 50 °C hot demineralized water pH adjusted to 7.0 until the conductivity in the permeate is below 100 pS. During the entire filtration the mean flux is 310 litres/m 2 /h.
20,0 kg of retentate from the microfiltration are collected and cooled to 80C in ice water, with pH 7.0, 0,58% protein, approx. 1000 ppm osteopontin and 4.1% dry matter. The retentate is spray dried in a NIRO tower drier and 0.7 kg of powder with 13,6% protein, approx. 2.3% osteopontin, and 96.4% dry matter is obtained. The dry matter consists of 80% ashes, 27% calcium and 13.8% phosphorus.
Example 2 2000 kg of casein whey with pH 4.55, 0,55% protein, approximately 20 ppm osteopontin and 4.53% dry matter are concentrated in a spiral UF PCT/DK01/00005 WO 01/49741 7 plant with membranes having a nominal pore size so that the proteins do not pass through the membrane. Typical pore size is 10,000D. The temperature during the filtration is 12 0 C and the mean pressure is 3.5 bars. Concentration is carried on until 1800 kg of permeate, which do not contain osteopontin, are removed. During the concentration mean flux is 27.6 litres/m 2 200 kg of retentate with pH 4.55, 3.97% protein, approx. 200 ppm osteopontin and 10.4% dry matter are left.
The 200 kg of retentate are pasteurized at 680 C for 15 sec and cooled to OC. Hereafter pH is adjusted to 7.0 with 6% NaOH.
After being allowed to stand for 30 min, microfiltration is carried out on 0.2 m 2 1.4 pm ceramic membranes at 50 °C with a mean pressure of 4.0 bars.
Diafiltration is performed with 50 OC hot demineralized water pH adjusted to until the conductivity in the permeate is below 100 pS. During the entire filtration the mean flux is 310 litres/m 2 20.0 kg of retentate from the microfiltration are collected and cooled to 8°C in ice water, with pH 7.0, 1.25% protein, approx. 2,000 ppm osteopontin and 8.3% dry matter.
The retentate is pH adjusted to 3.0 with 28% hydrochloric acid. which produces an almost clear solution.
This pH 3.0 adjusted solution is ultrafiltered at 10 OC and the mean pressure 4.0 bars on a membrane with a cut-off value of 5,000D. The retentate is diafiltered with demineralized water until the conductivity in the permeate is below 0.1 pS. During the entire filtration the mean flux is 17.8 litres/m 2 kg of retentate with 2.42% protein, approx. 4,000 ppm osteopontin and 2.6% dry matter are collected.
The retentate is spray dried in a NIRO tower drier and 0.2 kg of powder with 89.6% protein, approx. 14.8% osteopontin, and 96.4% dry matter is obtained.
Example 3 1000 kg of preconcentrated casein whey with pH 4.55, 3.76% protein, approx. 200 ppm osteopontin and 10.3% dry matter are pasteurised PC1IDKO/00005 n«r fn*9j WV U11/49Y1 8 at 670C for 15 sec and ,ooled to 50°C. Hereafter pH is adjusted to 7.0 with 6% NaOH.
After being allowed to stand for 60 min, microfiltration is carried out on 2.8 m 2 1.4 pm ceramic membranes at 50 o C with a mean pressure of 4.0 bars.
Diafiltration is performed with 50 oC hot demineralized water pH adjusted to until the conductivity in the permeate is below 100 iS. During the whole filtration the mean flux is 325 litres/m 2 /h.
100 kg of retentate from the microfiltration with pH 7.0, 1.22% protein, approx. 2,000 ppm osteopontin and 8.3% dry matter are collected and cooled to 5 °C on a plate heat exchanger.
The retentate is pH adjusted to 3.0 with 28% hydrochloric acid, which produces an almost clear solution. This pH 3.0 adjusted solution is ultrafiltered at 100C and the mean pressure 4.0 bars on a membrane with a cut-off value of 5,000D. The retentate is diafiltered with demineralized water until the conductivity in the permeate is below 100 pS. Then diafiltration is performed with 0.45 M KH 2
PO
4 with pH=4.5 until pH is 4.5 in the retentate. During the entire filtration the mean flux is 15.9 litres/m 2 10 kg retentate with 12.1% protein, approx. 20,000 ppm osteopontin and 13.4% dry matter are collected.
The retentate is pumped through a column with an anion exchanger which is equilibrated with 0.45 M KH 2
PO
4 with pH 4.5. Thus osteopontin is bound to the column while the greater part of other whey proteins is not bound. The column is washed with 0.45 M KH 2
PO
4 with pH 4.5 until the absorption at 280 nm is 0.
Osteopontin is eluted from the anion exchanger with 0.7 M KH 2
PO
4 with pH 4.5 until the absorption at 280 nm is 0 and 50 litres of eluate containing 500 g protein, of which 40% is osteopontin, are collected. The eluate is concentrated and diafiltered to remove salts on ultrafiltration membranes having a pore size of 5,000 D, at 10 OC and the mean pressure 4.0 bars. 5 kg of retentate with 10.7% dry matter, approx. 4% osteopontin, and 9.6% protein are collected. The retentate is spray dried in a NIRO tower drier and 0.5 kg of powder with 86.0% protein, approx. 36% osteopontin. and 95.8% dry matter is obtained.
PCT/DKO 1/00005 wO n1/49741 9 Example 4 1000 kg of casein whey with pH 4.56, 0,52% protein, approx. 20 ppm osteopontin and 4.50% dry matter are pasteurised at 71 OC for 15 s and cooled to 50 OC. Hereafter pH is adjusted to 7.0 with 6% NaOH.
After being allowed to stand for 2 hours, microfiltration is performed on 1.4 m 2 1.4 pm ceramic membranes at 50 °C with a mean pressure of 4.0 bars.
Diafiltration is performed with 50 OC hot demineralized water pH adjusted to until the conductivity in the permeate is below 100 pS. During the entire filtration the mean flux is 520 litres/m 2 /h.
30.0 kg of retentate from the microfiltration are collected and cooled to 8 °C with ice water, with pH 7.0, 0.78% protein, approx. 670 ppm osteopontin and 16.1% dry matter. The retentate is spray dried in a NIRO tower drier and 4.5 kg of powder with 4.7% protein, approx. 0,4% osteopontin, and 96.4% dry matter are obtained. The dry matter consists of 85% ashes, 27% calcium and 13.8% phosphorus.
Example 5000 kg of casein whey with pH 4.56, 0.51% protein, approx. 20 ppm osteopontin and 4.50% dry matter are pasteurised at 69 OC for 15 sec and cooled to 50 0 C. Hereafter pH is adjusted to 7.0 with 6% NaOH.
After being allowed to stand for 2 hours, microfiltration is performed on 1.4 m 2 1.4 pm ceramic membranes at 50 °C with a mean pressure of 4.0 bars.
Diafiltration is carried out with 50 OC hot demineralized water pH adjusted to until the conductivity in the permeate is below 100 pS. During the entire filtration the mean flux is 550 litres/m 2 /h.
150 kg of retentate from the microfiltration are collected and cooled to 8 C in ice water, with pH 7.0, 0,73% protein, approx 670 ppm osteopontin and 16.4% dry matter.
The retentate is pH adjusted to 3.0 with 28% hydrochloric acid, which produces an almost clear solution. This pH 3.0 adjusted solution is ultrafiltered at 10 °C and the mean pressure 4.0 bars on a membrane with a cut-off value of PCT/DKO1/00005 WO 01149741 10,000 D. The retentate is diafiltered with demineralized water until the conductivity in the permeate is below 100 pS. During the entire filtration the mean flux is 25.3 litreslm 2 10 kg of retentate with 11.0% protein, approx.
10,000 ppm osteopontin and 12.6% dry matter are collected.
The retentate is spray dried in a NIRO tower drier and 1.1 kg of powder with 83.8% protein, approx. 7.6% osteopontin, and 96.2% dry matter are obtained.
Example 6 10,000 kg of casein whey with pH 4.56, 0.54% protein, approx. 20 ppm osteopontin and 4.50% dry matter are pasteurised at 69 oC for sec and cooled to 50 oC. Hereafter pH is adjusted to 7.0 with 6% NaOH.
After being allowed to stand for 2 hours, microfiltration is performed on 2.8 m 2 1.4 im ceramic membranes at 50 oC with a mean pressure of 4.0 bars.
Diafiltration is carried out with 50 oC hot demineralized water pH adjusted to 7.0 until the conductivity in the permeate is below 100 pS. During the entire filtration the mean flux is 570 litres/m 2 /h.
300 kg of retentate from the microfiltration are collected and cooled to 8 o C in ice water, with pH 7.0, 0.76% protein, approx. 670 ppm osteopontin and 16.3 dry matter.
The retentate is pH adjusted to 3.0 with 28% hydrochloric acid, which produces an almost clear solution. This pH 3.0 adjusted solution is ultrafiltered at °C and the mean pressure 4.0 bars on a membrane with a cut-off value of 10,000 D. The retentate is diafiltered with demineralized water until the conductivity in the permeate is below 100 pS. During the entire filtration the mean flux is 24.6 litreslm 2 20 kg of retentate with 10.8% protein, approx.
10,000 ppm osteopontin and 12.3% dry matter are collected.
The retentate is pumped through a column with an anion exchanger which is equilibrated with 0.45 M KH 2 PO4 with pH 4.5. The osteopontin is thus bound to the column, while the greater part of other whey proteins is not PCT/DK01/00005 WO 01/49741 11 bound. The column is washed with 0.45 M KH 2
PO
4 with pH 4.5 until the absorption at 280 nm is 0.
Osteopontin is eluted from the anion exchanger with 0.7 M KH 2 PO4 with pH until the absorption at 280 nm is 0 and 50 litres of eluate containing 560 g of protein, of which 36% is osteopontin, are collected. The eluate is concentrated and diafiltered to remove salts on ultrafiltration membranes having a pore size of 5,000 D, at 10 C and the mean pressure 4.0 bars. 5 kg of retentate with 12.3% dry matter, approx. 4% osteopontin, and 11.2% protein are collected. The rententate is spray dried in a NIRO tower drier and 0.6 kg of powder with 87.6% protein, approx. 31% osteopontin, and 96.2% dry matter is obtained.
Example 7 10,000 kg of casein whey with pH 4.53, 0,55% protein, approx. 20 ppm osteopontin and 4.50% dry matter are ultra-/diafiltered in a spiral
UF
plant with membranes having a nominal pore size so that the proteins do not pass through the membrane. Typical pore size is 20,000D. The temperature during the filtration is 15 °C and the mean pressure is 3.5 bars. Once the filtration is terminated, 152 kg of retentate with pH 4,54, 23.1% protein, approx. 1,300 ppm osteopontin and 28.7% dry matter are collected During the concentration mean flux is 25.6 litres/m 2 The 152 kg of retentate are diluted with 722 kg of demineralized water so that the protein content is pH is adjusted to 7.4 with 6% NaOH. Then heat treatment is performed at 850C for 30 minutes and cooling to 8 'C is carried out. 6.4 kg of CaCI2 2H 2 0 is added to the heat treated retentate, and pH is adjusted to 4.2 with 6% hydrochloric acid.
After being allowed to stand for at least 2 hours (or to the next day), heating to 50 oC is performed and microfiltration is carried out on 1.4 m 2 0.8 im ceramic membranes at 50 OC with a mean pressure of 4.0 bars. Diafiltration is carried out with 50 o C hot demineralized water pH adjusted to 4.2 until the conductivity in the permeate is below 100 iS. During the filtration the mean flux is 415 litres/m 2 A total of 2,000 litres of permeate having continuously being cooled to 8 OC over a plate heat exchanger with pH 4.2, 0.16% pCT/DK01/00005 WO 01/49741 12 protein, approx. 100 ppm osteopontin and 4.1% dry matter is collected.
The permeate from the microfiltation is pH adjusted to 6.6 with 6% NaOH and it is ultra/diafiltered in a spiral UF plant at 100C with a mean pressure of bars until the conductivity in the permeate is below 500 pS. A filtration on membranes having a pore size of 5,000 D is carried out. 40 kg of retentate with pH 6.5, 7.9% protein, approx. 5,000 ppm osteopontin and 9.6% dry matter is collected.
The retentate is spray dried in a NIRO tower drier and 3.5 kg of powder with 79.2% protein, approx. 5.0% osteopontin, and 96.2% dry matter is obtained.
Example 8 200 kg of casein whey retentate with pH 4.55, 23.2% protein, approx. 1,300 ppm osteopontin and 29.1% dry matter are diluted with 1,000 kg of demineralized water and pH is adjusted to 7.4 with 6% NaOH. Then heat treatment is carried out at 85 C for 30 min and cooling to 8 °C is performed.
8.8 kg of CaCl2.2H 2 0 are added to the heat treated retentate; and pH is adjusted to 4.1 with 6% hydrochloric acid.
After standing for at least 2 hours (or to the next day), heating to 50 C is performed and microfiltration is carried out on 2.8 m 2 0.8 im ceramic membranes at 50 C with a mean pressure of 4.0 bars. Diafiltration is performed with 50 °C hot demineralized water pH adjusted to 4.1 until the conductivity in the permeate is below 100 pS. During the entire filtration the mean flux is 445 litres/m 2 A total of 2,800 litres of permeate having been cooled to 8 oC over a plate heat exchanger with pH 4.1, 0.16% protein, approx. 100 ppm osteopontin and 4.0% dry matter is collected.
The permeate from the microfiltration is pH adjusted to 6.6 with 6% NaOH and it is ultra/diafiltered in a spiral UF plant at 10 °C with a mean pressure of bars until the conductivity in the permeate is below 500 pS. A filtration is carried out on membranes having a pore size of 5,000 D. 40 kg of retentate with pH 6.5, 11.2% protein, approx. 6,500 ppm osteopontin and 12.4% dry matter is collected.
13 The retentate is pumped through a column with an anion exchanger which is equilibrated with 0.45 M KH 2 POI with pH 4.5 Osteopontin is thus bound to the column, while the greater part of other proteins is not bound. The column is washed with 0.45 M KH 2
PO
4 with pH 4.5 until the absorption at 280 nm is0.
Osteopontin is eluted from the anion exchanger with 0 7 M KH 2
PO
4 with pH until the absorption at 280 nm is 0 and 50 1 of eluate containing 500 g of protein, of which 50% is osteopontin, are collected. The eluate is concentrated and diafiltered to remove salts on ultrafiltration membranes having a pore size of 5,000 D, at 10 °C and the mean pressure 4 0 bars. 5 kg of retentate with 10.7% dry matter, approx. 5% osteopontin, and 9.6% protein are collected. The retentate is spray dried in a NIRO tower drier and 0.5 kg of powder with 86.0% protein, approx. 45% osteopontin, and 95,8% dry matter is obtained.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
o oooo

Claims (1)

14- THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A process for isolation of osteopontin from milk by pH adjustement, wherein a milk material containing osteopontin and a material containing calcium are mixed to obtain a calcium concentration of 0.05-0.2% and is pH adjusted to 3.5 to 5.0 to keep osteopontin in solution while precipitating other milk constituents or to 6.0 to 8.5 to aggregate or bind osteopontin while removing other milk constituents in solution. 2. A process according to claim 1, wherein that the milk material is mixed with a soluble calcium salt and pH is adjusted to 3.5 to 5.0 to keep the osteopontin in solution while precipitating other milk constituents. 3. A process according to claim 2, wherein pH is adjusted to pH 4.0 to 4.6. 4. A process according to claim 2, wherein pH is adjusted to pH about 4.2. 5. A process according to claim 2, wherein the soluble calcium source is *calcium chloride. 15 6. A process according to claim 1, wherein the milk material is mixed with an insoluble calcium salt and pH is adjusted to 6.0 to 8.5 to bind or aggregate the osteopontin while precipitating it without precipitating the major part of the other milk constituents. 7. A process according to claim 6, wherein pH is adjusted to pH 6.5 to 20 8. A process according to claim 6, wherein pH is adjusted to pH about 7. 9. A process according to claim 1, wherein the process is carried out stepwise, and at least one step involves a soluble material containing calcium and pH 3.5 to 5.0 and at least another step involves an insoluble material containing calcium and pH 6.0 to 10. A process according to claim 1, wherein the milk material containing osteopontin is a whey product. 11. A process according to claim 1, wherein the milk material containing osteopontin is a concentrated whey product. 12. A process according to claim 1, wherein the milk material containing osteopontin is a whey product from chemical acidifying of milk. 13. A process according to claim 2 or 6, wherein the milk material containing osteopontin and the material containing calcium are mixed so that the Ca- concentration is about 0.2 14. A process according to any one of claims 1 to 13 substantially as hereinbefore described. DATED this 15 th day of November, 2005 Aria Foods Amba By DAVIES COLLISON CAVE Patent Attorneys for the Applicants ooooo* *O•
AU23528/01A 2000-01-07 2001-01-04 A process for isolation of osteopontin from milk Expired AU784322B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200000013 2000-01-07
DKPA200000013 2000-01-07
PCT/DK2001/000005 WO2001049741A2 (en) 2000-01-07 2001-01-04 A process for isolation of osteopontin from milk

Publications (2)

Publication Number Publication Date
AU2352801A AU2352801A (en) 2001-07-16
AU784322B2 true AU784322B2 (en) 2006-03-09

Family

ID=8158885

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23528/01A Expired AU784322B2 (en) 2000-01-07 2001-01-04 A process for isolation of osteopontin from milk

Country Status (16)

Country Link
US (1) US7259243B2 (en)
EP (1) EP1244702B1 (en)
JP (1) JP4615173B2 (en)
KR (1) KR100733538B1 (en)
AR (1) AR027507A1 (en)
AT (1) ATE324378T1 (en)
AU (1) AU784322B2 (en)
CA (1) CA2396519C (en)
DE (1) DE60119077T2 (en)
DK (1) DK1244702T3 (en)
ES (1) ES2258520T3 (en)
NO (1) NO330264B1 (en)
NZ (1) NZ519492A (en)
PT (1) PT1244702E (en)
RU (1) RU2264734C2 (en)
WO (1) WO2001049741A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507335A (en) * 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
GB0227886D0 (en) * 2002-11-29 2003-01-08 Medical Res Council Prion inhibition
RU2379975C2 (en) * 2003-09-18 2010-01-27 Арла Фудс Амба Additive for baby food composition
KR20130009866A (en) * 2003-09-18 2013-01-23 아를라 푸즈 에이엠비에이 Infant formula
EP1625877A3 (en) * 2004-08-09 2006-03-08 Friesland Brands B.V. Functional milk fraction
AU2006324080B2 (en) * 2005-12-06 2012-04-12 Vifor (International) Ag Process for the preparation of ferri-succinylcasein
FR2901796A1 (en) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement PROCESS FOR EXTRACTING ONE OR MORE PROTEINS PRESENT IN MILK
WO2009027284A1 (en) * 2007-08-31 2009-03-05 Laboratoires Serono Sa Purification of osteopontin
US9783996B2 (en) 2007-11-19 2017-10-10 Valinge Innovation Ab Fibre based panels with a wear resistance surface
GB0813015D0 (en) * 2008-07-16 2008-08-20 Plant Bioscience Ltd Phosphoproteins and use of the same
EP2681230B1 (en) 2011-03-03 2015-12-16 Arla Foods Amba Method for isolating osteopontin using feeds containing caseino macropeptide (cmp)
US20150344534A1 (en) * 2011-12-07 2015-12-03 Arla Foods Amba Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants
EP2830647A1 (en) * 2012-03-28 2015-02-04 Arla Foods amba Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles
JP6509833B2 (en) 2013-07-05 2019-05-08 アーラ フーズ エエムビエArla Foods amba Mammalian milk osteopontin for enhancing immune responsiveness
EP3538053A1 (en) 2016-11-08 2019-09-18 Dentherapy Ltd Compositions comprising fluoride and calcium and method for preparing them
EP3544994B1 (en) 2016-11-27 2024-09-25 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from microalgae
GB202010987D0 (en) 2020-07-16 2020-09-02 Dentherapy Ltd Oral care compositions and methods
CN117377391A (en) * 2021-04-19 2024-01-09 雀巢产品有限公司 Use of milk protein fraction as a source of osteopontin
GB202110114D0 (en) 2021-07-14 2021-08-25 Dentherapy Ltd Oral care compositions for use in treaatment
CN118042933A (en) 2021-07-20 2024-05-14 阿拉食品公司 Method for preparing a whey-derived composition enriched in phospholipids and osteopontin, the composition itself and the nutritional use of the composition
CN115073580A (en) * 2022-06-22 2022-09-20 黑龙江飞鹤乳业有限公司 Osteopontin isolation method
WO2024056840A1 (en) 2022-09-16 2024-03-21 Univerza V Ljubljani Isolation of osteopontin and glycomacropeptide from whey
WO2025008636A1 (en) 2023-07-06 2025-01-09 Dentherapy Ltd Oral care compositions for use in the treatment of dental health conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0322971A (en) * 1989-06-20 1991-01-31 Calpis Food Ind Co Ltd:The Purification method and growth material of Bifidobacterium growth material
CH681543A5 (en) 1990-04-27 1993-04-15 Nestle Sa

Also Published As

Publication number Publication date
WO2001049741A2 (en) 2001-07-12
AU2352801A (en) 2001-07-16
KR100733538B1 (en) 2007-06-28
NO330264B1 (en) 2011-03-14
CA2396519C (en) 2011-03-22
EP1244702B1 (en) 2006-04-26
DK1244702T3 (en) 2006-08-28
RU2264734C2 (en) 2005-11-27
ATE324378T1 (en) 2006-05-15
US20030149249A1 (en) 2003-08-07
WO2001049741A3 (en) 2002-01-17
DE60119077T2 (en) 2006-09-07
KR20020073159A (en) 2002-09-19
JP4615173B2 (en) 2011-01-19
PT1244702E (en) 2006-08-31
ES2258520T3 (en) 2006-09-01
AR027507A1 (en) 2003-04-02
RU2002118313A (en) 2004-02-20
EP1244702A2 (en) 2002-10-02
JP2003519239A (en) 2003-06-17
NZ519492A (en) 2003-03-28
DE60119077D1 (en) 2006-06-01
NO20023057D0 (en) 2002-06-24
CA2396519A1 (en) 2001-07-12
US7259243B2 (en) 2007-08-21
NO20023057L (en) 2002-06-24

Similar Documents

Publication Publication Date Title
AU784322B2 (en) A process for isolation of osteopontin from milk
EP0488589B1 (en) Process for producing kappa-casein glycomacropeptides
US5280107A (en) Process for producing K-casein glycomacropeptides
Lisak Jakopović et al. Physiological significance, structure and isolation of α-lactalbumin
AU774203B2 (en) Whey protein concentrate and method of producing the same
EP0291264B1 (en) Process for the production of k-casein glycomacropeptide
JP2881044B2 (en) Method for producing kappa-caseino-glycomacropeptide
CA2344510A1 (en) Method for producing milk calcium composition
JP3236828B2 (en) Milk calcium composition
KR20150114968A (en) Method of producing beta-casein compositions and related products
AU651148B2 (en) A process for the manufacture of a milk fraction with a high-alfa-lactalbumin content and a product comprising the same
EP0580694B1 (en) Production of phosphopeptides from casein
AU2019243464B2 (en) Method for producing composition containing kappa-casein glycomacropeptide
JPH05320066A (en) Ostepblast multiplication-stimulating and bone-strengthening factor originated from whey and bone-strengthening food, medicine and feed containing the factor
US6462181B1 (en) Process for preparing a kappa-caseino glycomacropeptide or a derivative thereof
IE920012A1 (en) Process for the separation of whey proteins and products¹obtained
TW200927257A (en) Method for seperating casein from casein-contained solution
JP2023149412A (en) METHOD FOR PRODUCING GLYCOMACROPEPTIDE AND α LACTALBUMIN-CONTAINING COMPOSITION
JPH02154639A (en) Production of milk mineral concentrate
AU5448801A (en) Method for microfiltration of milk or colostral whey

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired